AQST – aquestive therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five [Yahoo! Finance]
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside [Yahoo! Finance]
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $17.00 price target on the stock.
Form 8-K Aquestive Therapeutics, For: Dec 19
Form 4 Aquestive Therapeutics, For: Dec 02 Filed by: BRATTON DOUGLAS K
Form 8-K Aquestive Therapeutics, For: Dec 02
Form 4 Aquestive Therapeutics, For: Nov 26 Filed by: Jung Cassie
Form SC 13G/A Aquestive Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.